Q1 Earnings Forecast for electroCore Issued By HC Wainwright

electroCore, Inc. (NASDAQ:ECOR) – Research analysts at HC Wainwright cut their Q1 2026 earnings estimates for shares of electroCore in a note issued to investors on Thursday, November 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.01) for the quarter, down from their prior estimate of $0.03. The consensus estimate for electroCore’s current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for electroCore’s Q2 2026 earnings at $0.04 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.16 EPS, FY2027 earnings at $1.29 EPS, FY2028 earnings at $2.17 EPS and FY2029 earnings at $2.80 EPS.

A number of other analysts have also weighed in on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of electroCore in a research note on Wednesday, October 8th. Wall Street Zen lowered electroCore from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $25.50.

electroCore Trading Down 3.9%

NASDAQ:ECOR traded down $0.23 during midday trading on Friday, hitting $5.61. 137,318 shares of the company traded hands, compared to its average volume of 112,349. The firm has a market capitalization of $44.88 million, a P/E ratio of -3.28 and a beta of 0.30. The firm’s fifty day moving average is $5.02 and its 200-day moving average is $5.61. electroCore has a 12-month low of $4.16 and a 12-month high of $19.49.

electroCore (NASDAQ:ECOR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.07). The company had revenue of $8.69 million for the quarter, compared to the consensus estimate of $7.84 million. electroCore had a negative return on equity of 308.23% and a negative net margin of 47.46%. electroCore has set its FY 2025 guidance at EPS.

Insider Buying and Selling at electroCore

In other electroCore news, Director Thomas J. Errico acquired 15,000 shares of the company’s stock in a transaction dated Monday, August 11th. The shares were purchased at an average cost of $4.47 per share, for a total transaction of $67,050.00. Following the completion of the purchase, the director owned 281,401 shares in the company, valued at approximately $1,257,862.47. This trade represents a 5.63% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 13.80% of the company’s stock.

Institutional Trading of electroCore

A number of hedge funds have recently bought and sold shares of ECOR. XTX Topco Ltd bought a new stake in electroCore during the 1st quarter valued at $90,000. Jump Financial LLC bought a new position in shares of electroCore in the 1st quarter worth $95,000. Cubist Systematic Strategies LLC bought a new stake in electroCore during the first quarter valued at about $153,000. Jaffetilchin Investment Partners LLC raised its holdings in electroCore by 26.7% in the second quarter. Jaffetilchin Investment Partners LLC now owns 41,783 shares of the company’s stock worth $221,000 after purchasing an additional 8,800 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in shares of electroCore by 114.4% in the 1st quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after buying an additional 19,599 shares in the last quarter. Hedge funds and other institutional investors own 26.74% of the company’s stock.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.